on 12 Mar 2024
Last Applicant/ Owned by
645 Summer Street, Suite 200
Boston
MA
02210
Serial Number
90332952 filed on 20th Nov 2020
Registration Number
7327850 registered on 12th Mar 2024
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve hearing, namely, genetically engineered tissues for inner ear Read More
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve hearing, namely, genetically engineered tissues for inner ear transplant purposes and drug delivery agents for use in the inner ear consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; gene therapy products, namely, biological preparations for the treatment of inner ear disorders and conditions; viral vectors, non-viral vectors and gene therapy vectors all for medical purposes, namely, therapeutic agents for delivering nucleic acid and other genetic material to nuclei of targeted cells in the human body, for use in gene therapy to treat inner ear disorders and conditions; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions
22nd Nov 2023
22nd Nov 2023
No 90332952
No Service/Collective Mark
No
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
12th Mar 2024 | REGISTERED-PRINCIPAL REGISTER |
12th Mar 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
03rd Feb 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
02th Feb 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
01st Feb 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
01st Feb 2024 | STATEMENT OF USE PROCESSING COMPLETE |
11th Jan 2024 | TEAS STATEMENT OF USE RECEIVED |
11th Jan 2024 | USE AMENDMENT FILED |
13th Sep 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
13th Sep 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |